PAGEInsider
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| NVCR | Leonard Frank X | Chief Executive Officer | Jun 04 '26 | Sale | 17.93 | 34,273 | 614,635 | 459,520 | Jun 05 |
| NVCR | Leonard Frank X | Chief Executive Officer | Mar 04 '26 | Sale | 13.31 | 5,607 | 74,603 | 493,793 | Mar 05 |
| NVCR | Leonard Frank X | Chief Executive Officer | Mar 02 '26 | Sale | 13.49 | 7,232 | 97,581 | 349,400 | Mar 03 |
| NVCR | Leonard Frank X | Chief Executive Officer | Feb 27 '26 | Sale | 13.66 | 9,734 | 133,003 | 338,011 | Mar 03 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Jun 02 '25 | Sale | 17.50 | 30,196 | 528,413 | 168,452 | Jun 04 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Mar 03 '25 | Sale | 18.54 | 2,527 | 46,841 | 143,673 | Mar 04 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Feb 28 '25 | Sale | 18.28 | 2,770 | 50,648 | 146,200 | Mar 03 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Feb 27 '25 | Sale | 20.02 | 12,266 | 245,609 | 148,970 | Mar 03 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Nov 01 '24 | Sale | 15.94 | 598 | 9,531 | 161,236 | Nov 04 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Mar 04 '24 | Sale | 16.01 | 840 | 13,448 | 160,098 | Mar 05 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Mar 01 '24 | Sale | 16.03 | 1,679 | 26,909 | 160,938 | Mar 05 |
| NVCR | Leonard Frank X | EVP, Pres., Novocure Oncology | Feb 28 '24 | Sale | 16.14 | 2,078 | 33,545 | 162,617 | Feb 29 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Mar 07 '23 | Sale | 75.16 | 8,318 | 625,205 | 54,284 | Mar 07 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Mar 03 '23 | Sale | 76.57 | 7,350 | 562,819 | 62,602 | Mar 07 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Mar 02 '23 | Sale | 75.36 | 4,951 | 373,113 | 58,144 | Mar 06 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Mar 01 '23 | Sale | 76.36 | 1,684 | 128,594 | 63,095 | Mar 02 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Jan 05 '23 | Sale | 119.05 | 10,471 | 1,246,577 | 46,158 | Jan 09 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Jan 05 '23 | Option Exercise | 13.91 | 28,026 | 389,777 | 53,984 | Jan 09 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Oct 13 '22 | Sale | 76.01 | 6,754 | 513,372 | 43,626 | Oct 17 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Oct 06 '22 | Sale | 84.37 | 6,754 | 569,835 | 50,380 | Oct 07 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Sep 29 '22 | Sale | 77.35 | 6,754 | 522,422 | 57,134 | Sep 30 |
| NVCR | Leonard Frank X | President, CNS Cancers US | Sep 22 '22 | Sale | 77.00 | 6,754 | 520,058 | 63,888 | Sep 26 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 15 '22 | Option Exercise | 7.15 | 5,517 | 39,447 | 82,913 | Sep 19 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 15 '22 | Sale | 88.52 | 12,271 | 1,086,222 | 70,642 | Sep 19 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 08 '22 | Sale | 81.48 | 6,754 | 550,316 | 77,396 | Sep 13 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 09 '22 | Sale | 88.00 | 1,863 | 163,944 | 84,150 | Sep 12 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 06 '22 | Sale | 78.57 | 1,384 | 108,741 | 86,013 | Sep 07 |
| NVCR | Leonard Frank X | Chief Development Officer | Sep 01 '22 | Sale | 76.96 | 1,750 | 134,677 | 92,875 | Sep 06 |
| NVCR | Leonard Frank X | Chief Development Officer | Aug 02 '22 | Sale | 69.66 | 414 | 28,839 | 102,193 | Aug 03 |
| NVCR | Leonard Frank X | Chief Development Officer | Mar 08 '22 | Sale | 70.10 | 744 | 52,154 | 102,295 | Mar 09 |
| NVCR | Leonard Frank X | Chief Development Officer | Mar 03 '22 | Sale | 70.41 | 555 | 39,076 | 103,039 | Mar 07 |